National Medical Stores

National Medical Stores (NMS) is a government-owned organization in Uganda, established in 1993 under the National Medical Stores Act. Headquartered in Entebbe, NMS is mandated to procure, store, and distribute essential medicines and medical supplies to all public health facilities across the country, including hospitals, health centers, and institutions associated with the police, army, and prisons. In August 2012, its mandate was further expanded to include the distribution of vaccines nationwide. (nms.go.ug)

Operating as a statutory corporation, NMS plays a pivotal role in Uganda's healthcare supply chain by ensuring the availability of quality medical commodities in public health facilities. The organization is governed by a 15-person board of directors, with a management team led by General Manager/CEO Moses Kamabare. (nms.go.ug)

NMS operates a comprehensive distribution network to ensure timely delivery of medical supplies across Uganda. The central warehouse is located in Kajjansi, approximately 21 kilometers northeast of the headquarters in Entebbe. This facility, completed in 2019, is equipped with state-of-the-art storage capabilities, including cold storage rooms and a quality control laboratory. Additionally, NMS has eight regional distribution centers strategically located in various districts to facilitate efficient delivery. (nms.go.ug)

The organization employs a GPS-monitored fleet to deliver medicines and supplies across all districts of Uganda, ensuring reliable and timely distribution to over 3,200 public health facilities. (nms.go.ug)

NMS serves as the primary wholesaler and distributor of essential medicines and medical supplies to public health facilities in Uganda. Its role is central to the country's healthcare supply chain, ensuring that government health facilities have access to necessary medical commodities. By managing procurement, storage, and distribution, NMS acts as a critical intermediary between pharmaceutical suppliers and healthcare providers. (nms.go.ug)

NMS's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 89.8% of total imports from India. This concentration suggests a strategic focus on key therapeutic areas, potentially leveraging volume discounts and streamlined logistics. However, such dependency may pose risks if there are disruptions in the supply of these specific products. The shipment data indicates a stable relationship with Indian suppliers, as evidenced by the consistent number of shipments over the years. For instance, CIPLA LIMITED has been a significant supplier, accounting for 49.9% of the total import value with 156 shipments. (nms.go.ug)

NMS's supply chain resilience is bolstered by its diversified supplier base, comprising 17 unique Indian suppliers. This diversity mitigates risks associated with over-reliance on a single supplier. The organization's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, ensures that products meet the necessary quality standards for direct use in healthcare settings. Additionally, the establishment of a modern warehouse in Kajjansi enhances storage capabilities and supply chain resilience. (nms.go.ug)

The concentrated sourcing pattern of NMS positions it to negotiate favorable terms with key suppliers, potentially securing better pricing and priority in supply. For Indian exporters, this presents an opportunity to strengthen relationships with NMS by ensuring consistent product quality and reliability. Suppliers that can offer a diverse range of products within the therapeutic areas prioritized by NMS may find increased opportunities for collaboration. (nms.go.ug)

The National Drug Authority (NDA) is the regulatory body responsible for overseeing the importation and distribution of pharmaceutical products in Uganda. Established under the National Drug Policy and Authority Act (Cap 206), the NDA ensures that medicines supplied in Uganda meet consistent high standards of quality, safety, and efficacy. (nda.or.ug)

The NDA's regulations stipulate that entities importing drugs into Uganda must possess a valid import license issued by the Authority. Additionally, a license to operate a pharmacy is required to be eligible for an import license. Each consignment of drugs must also receive a Verification Certificate from the NDA prior to importation. (nda.or.ug)

Import licensing in Uganda is governed by the National Drug Policy and Authority Act and associated regulations. Entities seeking to import drugs must obtain an import license from the NDA, which is valid for one year. To be eligible for this license, the entity must hold a valid license to operate a pharmacy. Furthermore, a Verification Certificate from the NDA is required for each consignment of drugs prior to importation. (nda.or.ug)

The NDA also enforces Good Manufacturing Practice (GMP) standards for pharmaceutical products. Manufacturers, including those from India, must comply with these standards to ensure product quality. The NDA conducts inspections of foreign manufacturing sites to verify compliance with GMP before approving marketing authorization applications. (nda.or.ug)

Pharmaceutical products imported into Uganda must undergo batch testing to ensure they meet the required quality standards. Stability requirements are enforced to guarantee that products remain effective throughout their shelf life. Labeling must be in English, and include essential information such as dosage instructions, storage conditions, and expiration dates. Serialization mandates are implemented to enhance traceability and prevent counterfeit products from entering the market. (nda.or.ug)

Between 2024 and 2026, the NDA has implemented stricter enforcement of import licensing requirements, emphasizing the need for valid import licenses and compliance with GMP standards. These changes aim to enhance the safety and efficacy of pharmaceutical products in Uganda. Additionally, the NDA has increased post-market surveillance to monitor the quality and safety of drugs available in the market. (nda.or.ug)

NMS's focus on antiviral and HIV medications (63.9%), nutritional supplements (18.0%), and antimalarial and antiparasitic drugs (18.0%) aligns with Uganda's public health priorities. The high import values of products like Dolutegravir ($4.8M) and Artemether ($1.6M) reflect the significant demand for these treatments. This strategic product selection is driven by the prevalence of HIV/AIDS and malaria in Uganda, necessitating a steady supply of effective medications. (nms.go.ug)

NMS's sourcing strategy emphasizes finished pharmaceutical formulations, ensuring that imported products are ready for direct use in healthcare settings. India's robust pharmaceutical manufacturing sector, known for its compliance with international quality standards, makes it a preferred source for these formulations. The diverse supplier base, including companies like CIPLA LIMITED and MYLAN LABORATORIES LIMITED, provides NMS with a reliable supply chain for essential medicines. (nms.go.ug)

By focusing on essential medicines and medical supplies, NMS serves the public healthcare sector in Uganda, including government hospitals, health centers, and institutions associated with the police, army, and prisons. Its role as a primary wholesaler and distributor positions it as a critical player in ensuring the availability of quality medical commodities in the public health system. (nms.go.ug)

There is a realistic opportunity for new Indian suppliers to collaborate with NMS, especially those offering a diverse range of products within the therapeutic areas prioritized by NMS. Suppliers that can demonstrate consistent product quality, reliability, and compliance with regulatory standards may find increased opportunities for collaboration. However, the existing supplier base is well-established, so new entrants must offer compelling value propositions to gain a foothold. (nms.go.ug)

Indian exporters seeking to supply NMS must ensure that their products comply with the NDA's GMP standards. They must also obtain marketing authorization from the NDA, which involves inspections of manufacturing sites and product evaluations. Additionally, products must meet the NDA's quality control requirements, including batch testing and stability assessments. (nda.or.ug)

Indian exporters should initiate contact with NMS by demonstrating their product's compliance with NDA standards and their ability to meet the specific needs of the Ugandan market. Participating in tenders and responding to NMS's procurement notices can provide avenues for collaboration. Understanding the regulatory filing process with the NDA and ensuring timely submission of required documentation is crucial.